Major depressive disorder (MDD) is considered a serious public health issue that adversely
impacts an individual's quality of life and contributes significantly to the global burden of …

The serotonin syndrome is a medication-induced condition resulting from serotonergic
hyperactivity, usually involving antidepressant medications. As the number of patients …

Aim: To conducted a systematic review and meta-analysis of prospective, randomized
controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools …

Background Pharmacogenomic testing guided treatment have been developed to guide
drug selection or conversion in major depressive disorder patients. Whether patients benefit …

Recommendations include using large prospective observational studies followed by
pragmatic trials rather than smaller, expensive controlled treatment trials for preliminary …

Advances in pharmacogenomics (PGx) have the potential to transform healthcare by
allowing precision medicine to become a reality. However, PGx knowledge is new, complex …

Objective: To identify and assess pharmacogenetic testing options relevant to psychiatry in
Canada. Method: Searches of published literature, websites, and Standard Council of …

Aim: To perform a meta-analysis of prospective, two-arm studies examining the clinical utility
of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform …

Mental disorders account for around one-third of disability worldwide and cause enormous
personal and societal burden. Current pharmacotherapies and nonpharmacotherapies do …

Objective Pharmacogenomic-based antidepressant treatment (PGATx) may result in more
precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy …